Clinical Stage IVA Gastric Cancer AJCC v8 Clinical Trials

14 clinical trials for Clinical Stage IVA Gastric Cancer AJCC v8 across international registries, including 3 currently recruiting participants. Compare status, phase, eligibility criteria and locations.

• PIPAC for the Treatment of Peritoneal Carcinomatosis in Patients With Ovarian, Uterine, Appendiceal, Colorectal, or Gastric Cancer — RECRUITING · PHASE1
• Personalized Neoantigen Peptide-Based Vaccine in Combination With Pembrolizumab for Treatment of Advanced Solid Tumors — RECRUITING · PHASE1
• Ramucirumab and Trifluridine/Tipiracil or Paclitaxel for the Treatment of Patients With Previously Treated Advanced Gastric or Gastroesophageal Junction Cancer — RECRUITING · PHASE2
• Pembrolizumab and Lenvatinib for the Treatment of Advanced, Unresectable, or Metastatic Gastroesophageal Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• Short-Course Chemoradiotherapy Followed by Chemotherapy for the Treatment of Resectable Gastric Adenocarcinoma — ACTIVE_NOT_RECRUITING · PHASE1
• Testing the Addition of Radiotherapy to the Usual Treatment (Chemotherapy) for Patients With Esophageal and Gastric Cancer That Has Spread to a Limited Number of Other Places in the Body — ACTIVE_NOT_RECRUITING · PHASE3
• Testing Immunotherapy (Atezolizumab) With or Without Chemotherapy in Locoregional MSI-H/dMMR Gastric and Gastroesophageal Junction (GEJ) Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Enhanced Outpatient Symptom Management to Reduce Acute Care Visits Due to Chemotherapy-Related Adverse Events — ACTIVE_NOT_RECRUITING · NA
• Paclitaxel for the Treatment of Gastric or Gastroesophageal Cancer — ACTIVE_NOT_RECRUITING · PHASE1
• Nivolumab, Ipilimumab and Chemoradiation in Treating Patients With Resectable Gastric Cancer — ACTIVE_NOT_RECRUITING · PHASE2
• Remote Telemonitoring of Patient-Generated Physiologic Health Data and Patient-Reported Outcomes — COMPLETED
• Real-Time Monitoring of Chemotherapy Side-Effects in Patients With Gastrointestinal Cancers, RT-CAMSS Study — COMPLETED · NA
• Pembrolizumab in Treating Patients With Metastatic or Unresectable Gastroesophageal Adenocarcinoma — COMPLETED · PHASE1
• IRX-2, Cyclophosphamide, and Pembrolizumab in Treating Participants With Recurrent or Metastatic Gastric or Gastroesophageal Junction Cancer — COMPLETED · PHASE1

Refine this search